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Abstract: Hydrolytic enantioselective cleavage of different racemic non-steroidal anti-inflammatory
drugs (NSAIDs) ester derivatives has been studied. An engineered esterase form Bacillus subtilis
(BS2m) significantly outperformed homologous enzymes from Halomonas elongata (HeE) and Bacillus
coagulants (BCE) in the enantioselective hydrolysis of naproxen esters. Structural analysis of the three
active sites highlighted key differences which explained the substrate preference. Immobilization of a
chimeric BS2m-T4 lysozyme fusion (BS2mT4L1) was improved by resin screening achieving twice
the recovered activity (22.1 ± 5 U/g) with respect to what had been previously reported, and was
utilized in a packed bed reactor. Continuous hydrolysis of ↵-methyl benzene acetic acid butyl ester
as a model substrate was easily achieved, albeit at low concentration (1 mM). However, the high
degree of insolubility of the naproxen butyl ester resulted in a slurry which could not be efficiently
bioconverted, despite the addition of co-solvents and lower substrate concentration (1 mM). Addition
of Triton® X-100 to the substrate mix yielded 24% molar conversion and 80% e.e. at a 5 mM scale
with 5 min residence time and sufficient retention of catalytic efficiency after 6 h of use.
Keywords: esterases; flow biocatalysis; enzyme immobilization; surfactants; NSAIDs
1. Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) are a group of propionic acid derivatives which
inhibit the cyclooxygenase (COX). Although normally commercialized as racemic mixtures, the specific
biological effect of these drugs is closely linked to their chirality [1–3].
Carboxylic ester hydrolases (EC 3.1.1.X) belong to a large group of enzymes that catalyze the
cleavage or formation of ester bonds. Carboxylesterases (EC 3.1.1.1) and lipases (EC 3.1.1.3), classified
based on their substrate specificity [4] are two different classes of hydrolytic enzymes, however, the
architecture of the hydrolases active site is highly conserved even among enzymes catalyzing different
reactions [5]. Thanks to their ability to stereoselectively hydrolyze or form esters they can be applied
to the preparation of NSAIDs [6,7].
Taking advantage of the lipase’s high resistance to organic media, the enantiopure preparation of
NSAIDs has been reported mainly by esterification with free or immobilized lipases in organic solvents
to overcome the poor solubility of such substrates in water [6–9]. More recently, Novozym435,
a commercially available immobilized lipase form Candida Antarctica (CALB), was applied in a
flow reactor for the continuous preparation of flurbiprofen in toluene [10]. However, conversion
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rates of these reactions are negatively affected by the presence of water, impacting consequently on
their scalability.
On the other hand, the stereoselective hydrolysis of NSAID’s esters can be performed in aqueous
solutions, yielding directly the active drug which contains the free carboxylic acid, and thus, their scale
up would be less problematic. Esterase catalyzed hydrolysis of racemic NSAIDs has been tested using
both soluble and immobilized enzymes [11–13]. However, very few examples are available on the
bio-catalyzed hydrolysis in a continuous flow reactors due to two main reasons: (1) the challenging
covalent-immobilization of esterases [14] and (2) the low water solubility of NSAIDs acid and its
esters derivatives in water [15]. The implementation of flow chemistry for insoluble substrates is
severely limited [16] due to possible blockages of the reactor, poor contact time with heterogeneous
immobilized catalysts, and low mass transfer. Where possible, solubility can be improved with the
addition of a co-solvent or the use of two-liquid phase systems [17,18]. These systems, however, rely
on the resistance of the biocatalyst to the organic solvent chosen and the partitioning of the substrate
in the two-phase set up, and, while in some cases they are beneficial for the separation of the product
form the substrate, this does not always apply if the solubility does not differ significantly.
In the present study, the enantioselective cleaving of naproxen and other NSAIDs ester derivatives
with three different esterases was studied. BS2m from Bacillus subtilis and BCE from Bacillus
coagulanswere previously described [19–21], while HeE from Halomonas elongata is a novel enzyme.
A comparison between the three active site architectures, paying particular attention to the tunnel
leading to the catalytic site, has been reported. Moreover, the immobilization of a chimeric BS2m-T4
lysozyme fusion (BS2mT4L1) [22], was optimized. The use of surfactants to address solubility issues
for flow applications was also explored.
2. Results
2.1. NSAID Hydrolysis
To better understand the applicability of carboxyl esterases for the hydrolysis of NSAIDs, three
homologous enzymes were used for comparison. BS2m, an engineered versatile esterase from Bacillus
subtilis [19,20], BCE from Bacillus coagulantswith a mini-lid similarly to the one found in lipases [21]
and HeE, a new esterase cloned form the halotolerant bacteria Halomonas elongata (Figure S1).
Following initial screening, HeE exhibited more activity against butyl esters (Table S1) similarly to
BS2m previously reported to have a better activity with p-nitrophenyl butyrate [19]. BCE, on the other
hand, had its maximum activity with ethyl esters [21]. Consequently, their ability to cleave NSAIDs
derivative was assessed with butyl esters for the first two and with ethyl esters for BCE.
The results of the batch hydrolysis of 10 mM substrate (1a–1c) are shown in Table 1. BS2m and
HeE achieved almost complete conversion with ibuprofen and flurbiprofen butyl ester over 8 h and
24 h, respectively. Both enzymes lacked any stereo-preference even at shorter reaction times. BCE
on the other hand gave its best results after 24 h yielding 22% and a 36% of the (S)-ibuprofen and
(S)-flurbiprofen, respectively (>97% e.e.). Naproxen behaved differently; BCE was completely unable
to hydrolyze the substrate, while both HeE and BS2m achieved moderate conversion after 48 h (35%
and 55%, respectively) however, BS2m displayed a significant degree of enantiopreference (80% e.e.
(R)-enantiomer, after 48 h with a conversion yield of 55%).
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Table 1. Maximum molar conversion (m.c.) and enantiomeric excess (e.e.) of the batch
biotransformations with all three enzymes and the substrates tested. A general scheme of the hydrolysis
reaction is shown. For conversions <5% e.e. could not be detected (n.d). All enzymes were used at
0.1 mg/mL.
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2.2. Active Site and Tunnel Architecture 
The architecture of the catalytic site and its proximities was probed by in-silico modeling to 
explain the different capability of accepting highly bulky substrates with low molecular flexibility 
such as naproxen. For both BS2m and HeE, models created with IntFold were used [23]. For BCE, the 
crystal structure of open-lid conformation was used (PDB: 5OLU).  
The catalytic triad was identical for the three esterases in terms of nature and positioning of the 
residues in the 3-dimensional structure. All three enzymes showed a similar positioning of the 
catalytic residues, and no notable difference was observed in the surrounding environment (see 
Figure 1). However, the geometry and biochemical characteristics of the tunnel leading to the active 
site [24], which was analyzed using Caver in a static structure [25], shown in Figure 2, were more 
revealing.  
 
Figure 1. Active site details of the three esterases. Bacillus coagulants (BCE), represented in red, 
Halomonas elongata (HeE) in blue, and Bacillus subtilis (BS2m) represented in yellow. The active triad 
as well as the residues forming the oxyanion hole is presented. 
From the different tunnels computed and predicted by the program, the shortest and with less 
restrictive bottleneck was chosen. BS2m predicted tunnel was less than 2 Å, and located very 
superficially in the protein, allowing easy access for any substrate. For HeE, the length increased 
more than three times, and for BCE the computed length was more than 10 Å (Table S2). Both tunnels 
of HeE and BCE showed bottlenecks of less than 2 Å and a curvature, suggesting serious 
impediments for non-flexible substrates to reach the active site. Moreover, the residues surrounding 
these entrances appear to be significant for substrate recognition and shuttling in HeE and BCE. The 
BCE tunnel is formed by 60% of hydrophobic chain amino acids, with Phe38 and Trp190 creating the 
1.29 Å bottleneck. This two residues could act as a gate as previously seen for acetylcholine esterases 
[26]. For HeE, the entrance is less constricted, with no obvious bottleneck and with the presence of 
residues with a charged side-chain (Arg132, Asp288 and Glu327). 
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2.2. Active Site and Tunnel Architecture
The architecture of the catalytic site a d its proximities as probed by in-silico modeling to
explain the differ t capability of accepting highly bulky substra es with low molecula flexibility
such a naproxen. F r both BS2m and HeE, model created with IntFold were used [23]. For BCE, the
crystal structure of open-lid conform ti n was us d (PDB: 5OLU).
The catalytic triad was identical for the three esterases in terms of nature nd positio ing of the
residues in the 3-dimensional structure. All three enzymes showed a similar positioni g of the catalytic
residues, and no notable difference was observed in the surrounding environment (see Figure 1).
However, the geometry and biochemical characteristics of the tunnel leading to the active site [24],
which was analyzed using Caver in a static structure [25], shown in Figure 2, were more revealing.
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dark blue for HeE (c). The catalytic serine is labelled in all structures.
From the different tunnels computed and predicted by the program, the shortest and with
less restrictive bottleneck was chosen. BS2m predicted tunnel was less than 2 Å, and located very
superficially in the protein, allowing easy access for any substrate. For HeE, the length increased more
than three times, and for BCE the computed length was more than 10 Å (Table S2). Both tunnels of
HeE and BCE showed bottlenecks of less than 2 Å and a curvature, suggesting serious impediments
for non-flexible substrates to reach the active site. Moreover, the residues surrounding these entrances
appear to be significant for substrate recognition and shuttling in HeE and BCE. The BCE tunnel
is formed by 60% of hydrophobic chain amino acids, with Phe38 and Trp190 creating the 1.29 Å
bottleneck. This two residues could act as a gate as previously seen for acetylcholine esterases [26]. For
HeE, the entrance is less constricted, with no obvious bottleneck and with the presence of residues
with a charged side-chain (Arg132, Asp288 and Glu327).
All together, these differences could explain the poor activity of HeE and BCE behavior towards
bulky, rigid substrates as naproxen esters. HeE showed some hydrolytic activity as its tunnel is more
flexible and prone to shuttle, allowing naproxen butyl ester to enter the catalytic site with less effort
than BCE for the corresponding ethyl ester.
2.3. Immobilization of BS2mT4L1 and Fl w Assisted Hydrolysis of Na roxen Butyl Ester
In order to exploit the hydrolysis of naproxen in flow, BS2m was chosen as it showed the highest
activity and selectivity. Covalent immobilization of esterases is generally problematic, resulting in
low recovered activity, as they tend to form a superficial layer on the carrier, hindering the substrate
diffusion [27,28]. We previously reported on the immobilization of a fusion protein of BS2m with
the T4 lysozyme (BS2mT4L1) on an epoxy derivatized methacrylate support (EC-403), which yielded
a biocatalyst with a comparable activity (6.2 ± 0.8 U/g) to Candida albicans lipase B, most used and
known as (CALB), using 16 times less enzyme [22].
To improve further the performance of the immobilized catalyst, higher catalyst loading was
tested. With a loading of 7.5 mg/g of resin, the biocatalyst displayed an activity of 11 ± 2 U/g
with respect to 6.2 ± 0.8 obtained previously. However, when this catalyst was tested in flow with
↵-methyl-benzene acetic acid butyl ester (↵MBBE; 1d) as a model substrate, no conversion was
observed. An upstream inlet of toluene (Figure 3a) allowed the recovery of the ester moiety, but
no hydrolysis occurred. Moreover, the presence of toluene affected dramatically the stability of the
immobilized biocatalyst, with only 25% of the initial activity after five cycles. Immobilization on a less
hydrophobic methacrylate resin (Relysorb® HG400) as well as on epoxy-functionalized agarose CL6B
(Ag-ep) [29] was trialed to increase hydrophilicity of the matrix while retaining the immobilization
chemistry. Both strategies yielded a biocatalyst with almost twice the activity of EP403-BS2mT4L1
(HG400-BS2mT4L1: 21 ± 3 U/g; Ag-ep-BS2mT4L1: 22.1 ± 5 U/g), however HG400-BS2mT4L1 in
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flow performed as the EC-403 preparation failing to convert the substrate. On the other hand,
Ag-ep-BS2mT4L1 yielded 40% product with ↵MBBE (1 mM).Catalysts 2019, 9, x FOR PEER REVIEW 5 of 10 
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Figure 3. (a) Scheme of the setup of the flow reactor with toluene and (b) outline of the final setup for
the enantioselective hydrolysis of naproxen.
However, when naproxen was tested under the same conditions, this did not lead to any product
formation. It is important to note that while ↵MBBE appeared as a clear solution, naproxen butyl
ester, even at 1 mM, is a suspension due to its highly hydrophobic nature. Suspensions, while they
can be used with a peristaltic pump system, could still potentially block the pump lines and the
interaction between the heterogenous biocatalyst and the particles is more challenging. A range of
water-miscible organic solvents (ethanol, methanol, DMSO and acetonitrile up to 20%) were tested in
order to solubilize the naproxen ester with no improvement. The use of surfactants in batch reactions
involving free enzymes and highly hydrophobic molecules such as profen esters had been reported
to enhance both the relative activity of the biocatalyst and the solubilization of the substrate but no
previous examples in flow or with immobilized catalyst is known. Triton® X-100, a nonionic surfactant,
showed the highest increase in the reaction rate without affecting the enantioselectivity using an
esterase from Pseudomonas sp. [12]. In this study, Triton® X-100 was added to the naproxen ester
suspension in low concentration, 0.5% (v/v), to minimize the distortion of the enzymatic structure and
effect on the activity [30,31], while improving naproxen butyl ester solubility. Under this conditions,
complete solubility of 1 and even 5 mM solution of naproxen butyl ester was achieved.
The surfactant enriched solution was applied in flow (Figure 3b) and the results are presented in
Table 2. Complete cleavage of the ester was observed within 30 min, while the batch reaction yielded
only a 55% conversion over 48 h. Moreover, since BS2m showed selectivity for the (R)-enantiomer
in the batch reactions, the retention time was shortened to see if a degree of enantiopreference could
be achieved. With 10 min residence time the conversion diminished to 65% but an e.e. of 40% was
obtained. Reducing further the residence time to 6 min the enantiomeric excess increased to 80% while
the conversion was 24%. The activity of the biocatalyst was then checked to assess the effect of Triton®
X-100 on its stability. After a total working time of six hours at a constant flow rate of 0.117 mL/min,
the biocatalyst retained still 57% of activity (12.5 ± 1 U/g).
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Table 2. Flow assisted hydrolysis of naproxen butyl ester. The substrate was prepared in 50 mM
phosphate buffer pH 8 with 5% DMSO and 0.5% of Triton® X-100. All reactions were performed at
37  C.
Naproxen Butyl Ester
Concentration (mM) Residence Time (minutes) Molar Conversion (%) e.e. (%)
1 mM 30 >99% <5%
5 mM
30 >99% <5%
10 65% 40%
6 24% 80%
3. Discussion
A comparative study of three different carboxylesterases, BCE, HeE and BS2m, highlighted
differences in the ability to hydrolyze NSAID’s esters. These could be partially explained by the
architecture of their tunnel leading to the active site. BS2m was significantly more active against
naproxen as the active site was more solvent exposed. In contrast, BCE presented a mini-lid structure
while HeE had the N-terminal ↵-helix partially covering the entrance to the active site. These
two structural features resulted in longer tunnels leading to the active site making the catalysis
of non-flexible substrates more challenging.
The immobilization of BS2mT4L1, previously reported, was enhanced by higher enzyme loading
and using a more hydrophilic matrix such as Relysorb® HG400 and agarose CL6B which lead to a
catalyst with 22 U/g of activity which almost doubled what was achieved with polymethacrylate
beads such as Relyzime® EC-403. The resulting biocatalyst was successfully applied in a packed bed
reactor for the continuous flow enantioselective hydrolysis of naproxen.
With the shorter retention time, a molar conversion of 24% and 80% e.e. was obtained. Therefore,
this exemplifies an enantioselective cleaving in mild conditions and buffered system with the use of
Triton® X-100 as a surfactant. The presence of Triton® X-100 helps to solubilize a highly hydrophobic
substrate such as naproxen butyl ester. Moreover, the biocatalyst showed a good operational stability
after 6 h, with 57% of retained activity.
In conclusion, the combination of a better immobilization strategy and the use of surfactant to
enhance the solubility of naproxen butyl ester enables the enantioselective hydrolysis. Finally, the
biocatalyst exhibited good stability in those conditions.
4. Materials and Methods
4.1. Halomonas elongata (HeE) Cloning
HELO_2889 was identified as a putative carboxylic-ester hydrolase by homology search using
Bacillus subtilis esterase para-nitrobenzyl esterase (PDB: 1QE3) and Bacillus coagulants (BCE) (PDB:
5OLU). The gene was amplified from Halomonas elongata DSM 2581 genome with the following
primers: 5’-CCC TGT GCG GGATCC TGA CGT CAT GCG CAA AGC TCA AGC 3’ and 5’-ATA
TAA A GGTACCT CAT CAG TTG ATC TGC AGG CTG TCC AGC GAC G-3’ using a Touchdown
PCR protocol. Primers were designed to incorporate a BamHI and KpnI restriction site respectively
(underlined). The amplified gene was cloned into a pRSET-b plasmid and transformed into chemically
competent E. coli BL21 (DE3) pLysS.
4.2. BS2m, HeE and BCE Production
BCE and Bacillus subtilis (BS2m) were expressed as previously described [19–21]. For HeE, E. coli
BL21(DE3) pLysS-HeE was grown at 37  C, 180 rpm in Terrific Broth media supplemented with
ampicillin (100 µg/mL) until the OD600 reached 0.6–0.8. Before the addition of 0.5 mM IPTG, the
culture was incubated in ice for 30 min, to enhance the expression as done with BCE, and subsequently
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grown for an additional 20 h at 30  C, 180 rpm. Cells were harvested by centrifugation (4500 rpms,
20 min) and resuspended in an appropriate volume of 50 mM potassium phosphate buffer pH 8.
1 mg/mL of lysozyme (Sigma Aldrich) was added, and the mixture stirred for 15 min at 37  C, 180 rpm.
After sonication (10 cycles 1 min on and 1 min off), cell debris were removed by centrifugation (1 h
at 4  C, 14,000 rpm). HeE was then purified by IMAC chromatography using an ÄKTA pure UPLC
(loading buffer: 50 mM potassium phosphate buffer, 0.3 M NaCl, 30 mM imidazole, pH 8; elution
buffer: 50 mM potassium phosphate buffer, 0.3 M NaCl, 300 mM imidazole, pH 8). The fractions
containing the pure protein were dialyzed against 50 mM potassium phosphate buffer pH 8 overnight.
4.3. Esterase Activity Assay
For the free enzymes, the activity was measured spectrophotometrically at 420 nm by determining
the formation of para-nitrophenol at 25  C in half-microcuvette (total volume 1 mL) for 5 min, taking a
measurement every 30 seconds. The reference conditions were 0.5 mM para-nitro phenylacetate (pNPA;
stock solution: 100 mM in acetone) 50 mM potassium phosphate buffer, pH 8. (" = 15000 M 1 cm 1).
BS2m had an activity of 61 U/mg, BS2mT4L1 of 32 U/mg, HeE of 3.5 U/mg and BCE an activity
of 0.03 U/mg against pNPA.
One unit (U) of activity is defined as the amount of enzyme which catalyzes the consumption of
1 µmol of para-nitrophenyl acetate per minute under reference conditions.
For the immobilized enzyme, activity was measured using 25–50 mg of resin in an appropriate
volume (10–20 mL) in the reference conditions. The solution was kept at 30  C with shaking and the
absorbance was measured every minute for 10 minutes.
4.4. Butyl-Ester NSAID’s Synthesis
A solution of racemic or enantiopure acid (250 mg, 1 eq), butanol (1.5 eq) and
4-dimethylaminopyridine (DMAP 0.12 eq) in CH2Cl2 (10 mL), was cooled down and 1.1 eq of
dicyclohexylcarbodiimide (DCC) were added. The reaction was monitored by TLC (9:1 n-hexane/ethyl
acetate) and once completed, filtered and washed with 5 mL of CH2Cl2. The crude was then purified
by flash chromatography (9:1 n-hexane/ethyl acetate). All synthesized molecules’ purity was checked
by HPLC and NMR (see Methods S1).
4.5. Batch Biotransformations with Free Enzymes
Biotransformations were performedwith 10mM suspensions of the corresponding ester derivative
and 0.1 mg/mL of enzyme in 50 mM potassium phosphate buffer pH 8 with 10% DMSO as cosolvent.
Samples of 100 µL were withdrawn at different times and the reaction was quenched by adding 450 µL
of HCl 0.2% and 450 µL of acetonitrile. The samples were analyzed by HPLC (Dionex UltiMate 3000,
Waters X-Bridge C18 (3.5 µm, 2.1 ⇥ 100 mm), 0.8 mL/min, measuring at 210 nm, 250 nm and 265 nm)
to assess the conversion. The retention times in minutes were: ↵-methyl benzyl acetic acid butyl ester
5.47, ↵-methyl benzyl acetic acid 3.98, flurbiprofen butyl ester 5.98, flurbiprofen acid 4.86, ibuprofen
butyl ester 6.22, ibuprofen acid 5.05, naproxen butyl ester 5.74, naproxen acid 4.52.
4.6. HPLC Analysis to Determine the Enantioselectivity
HPLC analyses were performed with a Jasco PU-980 pump equipped with a UV–vis detector Jasco
UV-975 (wavelength: 254 nm). Column: Lux Amylose-2, 4.60 mm i.d. x 150 mm, Phenomenex. Eluent:
acetonitrile:water:formic acid (1:1:0.2, v/v/v). Flow: 1.0 mL/min. Retention times: (R)-Flurbiprofen
4.3 min; (S)-Flurbiprofen 5.7 min; (R)-Flurbiprofen ethyl ester 28.2 min; (S)-Flurbiprofen ethyl ester
36.1 min; (R)-Flurbiprofen butyl ester 29.8 min; (S)-Flurbiprofen butyl ester 37.8 min. Column Lux
Cellulose-3, 4.60 mm i.d. x 150 mm, Phenomenex. Eluent n-hexane:2-propanol:formic acid (98:2:0.1,
v/v/v). Flow: 1.0 mL/min. Retention times: (R)-Ibuprofen butyl ester 4.0 min; (S)-Ibuprofen butyl
ester 4.6 min; (R)-Ibuprofen ethyl ester 4.3 min; (S)-Ibuprofen ethyl ester 5.0 min; (R)-Ibuprofen 7.9 min;
(S)-Ibuprofen ethyl ester 8.7 min. Column Lux Cellulose-1, 4.60 mm i.d. x 150 mm, Phenomenex. Eluent
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n-hexane:2-propanol:formic acid (92:8:0.1, v/v/v). Flow: 1.0 mL/min. Retention times: (R)-Naproxen
butyl ester 5.0 min; (S)-Naproxen butyl ester 6.1 min; (R)-Naproxen ethyl ester 5.6 min; (S)-Naproxen
ethyl ester 6.5 min; (R)-Naproxen 10.5 min; (S)-Naproxen 11.2 min.
4.7. Computational Analysis of Tunnels
The analysis of the tunnel leading to the catalytic site of the different esterases was performed
using CAVER 3.0 plugin for Pymol [25] selecting as endpoint the catalytic serine. When available,
crystal structures of the proteins were used, or homology models were created using the IntFold
server [23].
4.8. Preparation of Agarose with Epoxide Groups
Preparation of agarose with epoxide groups (Ag-ep) was prepared and the quantification of
epoxide was conducted as described before [29]. In all batches, the resin contained 60 ± 4 µmols of
epoxides/g of dry resin.
4.9. Immobilization of BS2mT4L1 in Epoxy-Agarose
BS2mT4L1 immobilization was optimized from Planchestainer et al. [22]. One gram of the
previously prepared Ag-ep was mixed with 2 mL of modification buffer (1 M Sodium borate, 2 M
iminodiacetic acid in 50 mM phosphate buffer Ph 8.5) and left shaking at room temperature for 2 h.
The mixture was filtered under vacuum and washed with abundant H2O before the addition of 5 mL
of metal buffer (1M NaCl, 45 mM CoCl2 in 50 mM phosphate buffer pH 6) and left to agitate for 2 h.
Following vacuum filtration and washing with H2O, the desired amount of protein was added
and left shaking overnight at room temperature. The mixture was then filtered under vacuum and
3 mL of desorption buffer (50 mM EDTA, 0.5 M NaCl in 20 mM phosphate buffer pH 7.2) were added
to eliminate the metal before the addition of blocking buffer (3 M glycine in 50 mM phosphate buffer
pH 8.5). The mixture was left shaking for 20 h and finally filtered and washed with H2O and the
biocatalyst was kept in 50 mM phosphate buffer pH 8.
4.10. Flow Reactions
Flow reaction were performed using a R2+/R4 flow reactor from Vapourtec using an Omnifit
glass column (6.6 mm ⇥ 100 mm length) filled with 10.2 g of biocatalyst for the longest residence time.
Initially, a solution of the substrate was prepared in 50 mM phosphate buffer with 10% DMSO. When
needed, the solution was mixed in a T-tube with toluene (2:1) upstream of the packed column.
For the resolution of racemic naproxen butyl ester, 5 mM of Naproxen butyl ester was prepared in
50 mM phosphate buffer with 0.5% (v/v) of Triton® X-100.
The flow rate was varied and optimized. Molar conversion and enantiomeric excess were assessed
by HPLC as previously described.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4344/9/3/232/s1,
Figure S1: SDS-gel of the purification of HeE, Table S1: kinetic parameters of HeE for para-nitrobenzyl acetate
and para-nitrobenzyl butyrate, Table S2: physical parameters of the calculated tunnels for BCE, BS2m and HeE,
Methods S1: NMR characterization of NSAIDs butyl esters.
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